Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results Back to the Newsroom Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results TAAPTM (Opioid Abuse Deterrent) Program Update Ensysce's lead drug candidate, PF614, is a Trypsin-Activated Abuse Protection (TAAPTM) extended-release oxycodone designed to deliver effective pain relief while incorporating built-in abuse protection. Through proprietary chemical modification of ox ...